Still, adding more Impella pumps is a big part of Abiomed's bottom line. The company booked $32.2 million in revenue during its fiscal 2012 third quarter, up 18% from the same period the previous year ...
Second Malignancies as a Consequence of Nucleoside Analog Therapy for Chronic Lymphoid Leukemias PURPOSE: To evaluate response and outcome with a front-line intensive multiagent chemotherapy regimen ...
Pediatric-inspired protocols and hyper-CVAD conferred comparable survival for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia, according to study ...
FERNDALE, Mich. -- A new study on securement for central vascular access devices (CVAD) suggests that subcutaneous anchor securement systems (SASS) are shown to be more effective at keeping central ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio SAN DIEGO — The addition of nelarabine to ...
Massachusetts-based heart support technologies major, Abiomed Inc. ( ABMD) has received the Health Canada nod to launch its Impella cVAD heart pump. Per the approval, the Impella cVAD can be used as a ...
A new study on securement for central vascular access devices (CVAD) suggests that subcutaneous anchor securement systems (SASS) are shown to be more effective at keeping central catheters in place, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback